[AMV] Amerikaanse politiek #836 Trump zegt ja tegen corona

September 29, 2020 at 4:01 PM EDT
Back
REGENERON'S REGN-COV2 ANTIBODY COCKTAIL REDUCED VIRAL LEVELS AND IMPROVED SYMPTOMS IN NON-HOSPITALIZED COVID-19 PATIENTS
TARRYTOWN, N.Y., Sept. 29, 2020 /PRNewswire/ --

Greatest improvements in patients who had not mounted their own effective immune response prior to treatment

Plan rapidly to discuss results with regulatory authorities

Regeneron to host investor and media webcast to discuss results at 4:30 pm ET today

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the first data from a descriptive analysis of a seamless Phase 1/2/3 trial of its investigational antibody cocktail REGN-COV2 showing it reduced viral load and the time to alleviate symptoms in non-hospitalized patients with COVID-19. REGN-COV2 also showed positive trends in reducing medical visits. The ongoing, randomized, double-blind trial measures the effect of adding REGN-COV2 to usual standard-of-care, compared to adding placebo to standard-of-care.

This trial is part of a larger program that also includes studies of REGN-COV2 for the treatment of hospitalized patients, and for prevention of infection in people who have been exposed to COVID-19 patients.

"After months of incredibly hard work by our talented team, we are extremely gratified to see that Regeneron's antibody cocktail REGN-COV2 rapidly reduced viral load and associated symptoms in infected COVID-19 patients," said George D. Yancopoulos, M.D., Ph.D., President and Chief Scientific Officer of Regeneron. "The greatest treatment benefit was in patients who had not mounted their own effective immune response, suggesting that REGN-COV2 could provide a therapeutic substitute for the naturally-occurring immune response. These patients were less likely to clear the virus on their own, and were at greater risk for prolonged symptoms. We are highly encouraged by the robust and consistent nature of these initial data, as well as the emerging well-tolerated safety profile, and we have begun discussing our findings with regulatory authorities while continuing our ongoing trials. In addition to having positive implications for REGN-COV2 trials and those of other antibody therapies, these data also support the promise of vaccines targeting the SARS-CoV-2 spike protein."

The descriptive analysis included the first 275 patients enrolled in the trial and was designed to evaluate anti-viral activity with REGN-COV2 and identify patients most likely to benefit from treatment; the next cohort, which could be used to rapidly and prospectively confirm these results, has already been enrolled. Patients in the trial were randomized 1:1:1 to receive a one-time infusion of 8 grams of REGN-COV2 (high dose), 2.4 grams of REGN-COV2 (low dose) or placebo. All patients entering the trial had laboratory-confirmed COVID-19 that was being treated in the outpatient setting. Patients were prospectively characterized prior to treatment by serology tests to see if they had already generated antiviral antibodies on their own and were classified as seronegative (no measurable antiviral antibodies) or seropositive (measurable antiviral antibodies). Approximately 45% of patients were seropositive, 41% were seronegative and 14% were categorized as "other" due to unclear or unknown serology status.

Key data findings include:
Note that since this analysis was considered descriptive, all p-values are nominal.

As hypothesized, patients in the study consisted of two different populations: those who had already mounted an effective immune response, and those whose immune response was not yet adequate. These populations could be identified serologically by the presence (seropositive) or absence (seronegative) of SARS-CoV-2 antibodies, and/or by high viral loads at baseline.
Serological status highly correlated with baseline viral load (p<0.0001). Seropositive patients had much lower levels of virus at baseline, and rapidly achieved viral loads approaching lowest levels quantifiable (LLQ), even without treatment. In contrast, seronegative patients had substantially higher viral levels at baseline, and cleared virus more slowly in the absence of treatment.
Serological status at baseline also predicted how rapidly patients had alleviation of their COVID-19 clinical symptoms. In the untreated (placebo) patients, seropositive patients had a median time to alleviation of symptoms of 7 days, compared to seronegative patients who had a median time to alleviation of symptoms of 13 days.
REGN-COV2 rapidly reduced viral load through Day 7 in seronegative patients (key virologic endpoint). The mean time-weighted-average change from baseline nasopharyngeal (NP) viral load through Day 7 in the seronegative group was a 0.60 log10 copies/mL greater reduction (p=0.03) in patients treated with high dose, and a 0.51 log10 copies/mL greater reduction (p=0.06) in patients treated with low dose, compared to placebo. In the overall population, there was a 0.51 log10 copies/mL greater reduction (p=0.0049) in patients treated with high dose, and a 0.23 log10 copies/mL greater reduction (p= 0.20) in patients treated with low dose, compared to placebo.
Patients with increasingly higher baseline viral levels had correspondingly greater reductions in viral load at Day 7 with REGN-COV2 treatment. The mean log10 copies/mL reduction in viral load compared to placebo were as follows:
- Viral load higher than 105 copies/mL: high dose (-0.93); low dose (-0.86) (p=0.03 for both); approximately 50-60% reduction compared to placebo
- Viral load higher than 106 copies/mL: high dose (-1.55); low dose (-1.65) (p<0.002 for both); approximately 95% reduction compared to placebo
- Viral load higher than 107 copies/mL: high dose (-1.79); low dose (-2.00) (p<0.0015 for both); approximately 99% reduction compared to placebo
Patients who were seronegative and/or had higher baseline viral levels also had greater benefits in terms of symptom alleviation. Among seronegative patients, median time to symptom alleviation (defined as symptoms becoming mild or absent) was 13 days in placebo, 8 days in high dose (p=0.22), and 6 days in low dose (p=0.09). Patients with increasing viral loads at baseline had correspondingly increasing benefit in time to symptom alleviation.
There were a small number of medically-attended visits given that most non-hospitalized patients recover well at home. Patients in the seronegative group were at higher risk of medically-attended visits: 10 of the 12 medically-attended visits (defined as hospitalizations, or emergency room, urgent care or telemedicine visits for COVID-19) occurred in patients who were seronegative at baseline. In the seronegative group, 15.2% of placebo-treated patients, 7.7% of patients treated with high dose and 4.9% of patients treated with low dose required additional medical visits.
Both doses were well-tolerated. Infusion reactions were seen in 4 patients (2 on placebo and 2 on REGN-COV2). Serious adverse events occurred in 2 placebo patients, 1 low dose patient and no high dose patients. There were no deaths in the trial.
More than 2,000 people have been enrolled across the overall REGN-COV2 development program, and no unexpected safety findings have been reported by the Independent Data Monitoring Committee.

"Thank you to the global investigators, sites and patients who continue to work with us to conduct REGN-COV2 trials, especially given the unique challenges posed by the pandemic," said David Weinreich, M.D., Senior Vice President and Head of Global Clinical Development at Regeneron. "We plan rapidly to submit detailed results from this analysis for publication in order to share insights with the public health and medical communities. Regeneron continues to enroll patients in this trial and all other ongoing late-stage trials evaluating REGN-COV2."

Additional Trial Background
Among the first 275 patients, approximately 56% were Hispanic, 13% were African American and 64% had one or more underlying risk factors for severe COVID-19, including obesity (more than 40%). On average, patients were 44 years of age. In total, 49% of participants were male and 51% were female.

At least 1,300 patients will be recruited into the Phase 2/3 portion of the outpatient trial overall. Patients will be followed for 29 days, with viral shedding in the upper respiratory tract assessed approximately every 2-3 days in the Phase 2 portion of the trial and clinical endpoints assessed via investigator and patient-reported data throughout.

In addition to this trial in non-hospitalized patients, REGN-COV2 is currently being studied in a Phase 2/3 clinical trial for the treatment of COVID-19 in hospitalized patients, the Phase 3 open-label RECOVERY trial of hospitalized patients in the UK and a Phase 3 trial for the prevention of COVID-19 in household contacts of infected individuals. Recruitment in all 4 trials is ongoing.

Investor and Media Webcast Information
Regeneron will host a conference call and simultaneous webcast to share updates on REGN-COV2 today September 29, 2020 at 4:30 pm ET. To access the call, dial (888) 660-6127 (U.S.) or (973) 890-8355 (International). A link to the webcast may be accessed from the "Investors and Media" page of Regeneron's website at www.regeneron.com. A replay of the conference call and webcast will be archived on the Company's website and will be available for at least 30 days.

About REGN-COV2
REGN-COV2 is a combination of two monoclonal antibodies (REGN10933 and REGN10987) and was designed specifically to block infectivity of SARS-CoV-2, the virus that causes COVID-19.

To develop REGN-COV2, Regeneron scientists evaluated thousands of fully-human antibodies produced by the company's VelocImmune® mice, which have been genetically modified to have a human immune system, as well as antibodies identified from humans who have recovered from COVID-19. The two potent, virus-neutralizing antibodies that form REGN-COV2 bind non-competitively to the critical receptor binding domain of the virus's spike protein, which diminishes the ability of mutant viruses to escape treatment and protects against spike variants that have arisen in the human population, as detailed in Science. Preclinical studies have shown that REGN-COV2 reduced the amount of virus and associated damage in the lungs of non-human primates.

REGN-COV2's development and manufacturing has been funded in part with federal funds from the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services under OT number: HHSO100201700020C. Regeneron has recently partnered with Roche to increase the global supply of REGN-COV2. If REGN-COV2 proves safe and effective in clinical trials and regulatory approvals are granted, Regeneron will manufacture and distribute it in the U.S. and Roche will develop, manufacture and distribute it outside the U.S.

About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to seven FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases and rare diseases.

Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite technologies, such as VelocImmune®, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.

For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.

Forward-Looking Statements and Use of Digital Media
This press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company"), and actual events or results may differ materially from these forward-looking statements. Words such as "anticipate," "expect," "intend," "plan," "believe," "seek," "estimate," variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the impact of SARS-CoV-2 (the virus that has caused the COVID-19 pandemic) on Regeneron's business and its employees, collaborators, and suppliers and other third parties on which Regeneron relies, Regeneron's and its collaborators' ability to continue to conduct research and clinical programs (including those discussed in this press release), Regeneron's ability to manage its supply chain, net product sales of products marketed by Regeneron and/or its collaborators (collectively, "Regeneron's Products"), and the global economy; the nature, timing, and possible success and therapeutic applications of Regeneron's Products and product candidates and research and clinical programs now underway or planned, including without limitation the development program relating to REGN-COV2 (Regeneron's investigational two-antibody cocktail for the treatment and prevention of COVID-19) discussed in this press release; the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron's product candidates (such as REGN-COV2) and new indications for Regeneron's Products; the extent to which the results from the research and development programs conducted by Regeneron and/or its collaborators (including without limitation the data from a descriptive analysis of a seamless Phase 1/2/3 trial evaluating REGN-COV2 discussed in this press release) may be replicated and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; safety issues resulting from the administration of Regeneron's Products and product candidates (such as REGN-COV2) in patients, including serious complications or side effects in connection with the use of Regeneron's Products and product candidates in clinical trials; uncertainty of market acceptance and commercial success of Regeneron's Products and product candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary), including those discussed in this press release, on any potential regulatory approval and/or the commercial success of Regeneron's Products and product candidates; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize Regeneron's Products and product candidates, including without limitation REGN-COV2; ongoing regulatory obligations and oversight impacting Regeneron's Products, research and clinical programs, and business, including those relating to patient privacy; the availability and extent of reimbursement of Regeneron's Products from third-party payers, including private payer healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payers and new policies and procedures adopted by such payers; competing drugs and product candidates that may be superior to, or more cost effective than, Regeneron's Products and product candidates; the ability of Regeneron to manufacture and manage supply chains for multiple products and product candidates; the ability of Regeneron's collaborators, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron's Products and product candidates; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license or collaboration agreement, including Regeneron's agreements with Sanofi, Bayer, and Teva Pharmaceutical Industries Ltd. (or their respective affiliated companies, as applicable), as well as Regeneron's collaboration with Roche relating to REGN-COV2 discussed in this press release, to be cancelled or terminated; and risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings relating to EYLEA® (aflibercept) Injection, Dupixent® (dupilumab), and Praluent® (alirocumab)), other litigation and other proceedings and government investigations relating to the Company and/or its operations (such as the pending civil litigation initiated by the U.S. Attorney's Office for the District of Massachusetts), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on Regeneron's business, prospects, operating results, and financial condition. A more complete description of these and other material risks can be found in Regeneron's filings with the U.S. Securities and Exchange Commission, including its Form 10-Q for the quarterly period ended June 30, 2020. Any forward-looking statements are made based on management's current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.

Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron's media and investor relations website (http://newsroom.regeneron.com) and its Twitter feed (http://twitter.com/regeneron).

Contacts:

Media Relations
Alexandra Bowie
Tel: +1 (914) 847-3407
alexandra.bowie@regeneron.com

Investor Relations
Mark Hudson
Tel: +1 (914) 847-3482
mark.hudson@regeneron.com

Cision View original content:http://www.prnewswire.com(...)ients-301140336.html

SOURCE Regeneron Pharmaceuticals, Inc.

Investor Relations
914.847.7741
invest@regeneron.com

Puddington	zaterdag 3 oktober 2020 @ 11:28
	President: Donald Trump Vice President: Mike Pence SPOILER: Het Kabinet-Trump Het kabinet: Secretary of State - Mike Pompeo Secretary of Treasury - Steven Mnuchin Secretary of Defense - Patrick M. Shanahan (Acting) Attorney General - William Barr Secretary of the Interior - David Bernhardt (Acting) Secretary of Agriculture - Sonny Perdue Secretary of Commerce - Wilbur Ross Secretary of Labor - Alexander Acosta Secretary of Health and Human Services - Alex Azar Secretary of Housing & Urban Development - Ben Carson Secretary of Transportation - Elaine Chao Secretary of Energy - Rick Perry Secretary of Education - Betsy DeVos Secretary of Veterans Affairs - Robert Wilkie Secretary of Homeland Security - Kirstjen Nielsen Cabinet-level officials: White House Chief of Staff - Mick Mulvaney (Acting) Trade Representative - Robert Lighthizer Director of National Intelligence - Dan Coats Ambassador to the UN - Jonathan Cohen (Acting) Director of the Office of Management & Budget - Mick Mulvaney Director of the Central Intelligence Agency - Gina Haspel Administrator of the Environmental Protection Agency - Andrew R. Wheeler (Acting) Administrator of the Small Business Administration - Linda McMahon Andere kopstukken: Ivanka Trump (Advisor to the President), Jared Kushner (Senior Adviser Strategic Planning), Stephen Miller (Senior Adviser Policy), John Bolton (National Security Adviser), Kellyanne Conway (Counselor), Donald McGahn (White House Counsel), Sarah Huckabee Sanders (Press Secretary), Christopher Wray (Director of the Federal Bureau of Investigation), Robert Mueller (Special Counsel), Rod Rosenstein (United States Deputy Attorney General). Verdwenen of voormalige kopstukken: Kabinet: Tom Price (HHS), David Shulkin (VA), Rex Tillerson (State) DOJ/FBI: Sally Yates, James Comey, Preet Bharara, Andrew McCabe Communicatie WH: Mike Dubke, Sean Spicer, Anthony Scaramucci, Hope Hicks Adviseurs enzo: Michael Flynn, Herbert McMaster, Reince Priebus, Rob Porter, Gary Cohn, Steve Bannon, John McEntee, General Jim 'Mad Dog' Mattis, Jeff Sessions. John F. Kelly, Ryan Zinke, Nikki Haley, Scott Pruitt Amerikaans Congres: Political groups house: Democratic (235) Republican (197) Vacant (3) Political groups Senate: Republican (53) Democratic (45) Independents (2) SPOILER: Overzicht van lopende onderzoeken Timeline of Russian interference in the 2016 United States elections Timeline of investigations into Trump and Russia (2017) Timeline of investigations into Trump and Russia (2018) Timeline of investigations into Trump and Russia (2019) SPOILER: Hoe werkt een impeachment? Van Arjen van der Horst (Nieuwsuur-correspondent). Hoe werkt een impeachmentprocedure? Een afzettingsprocedure kun je niet zomaar beginnen. Er moet sprake zijn van een serieuze schending van de wet. Artikel II van de Amerikaanse grondwet formuleert het zo: “The President, Vice President, and all civil Officers of the United States shall be removed from Office on Impeachment for, and conviction of, Treason, Bribery, or other High Crimes and Misdemeanors.” Het Congres fungeert bij een afzettingsprocedure als een soort rechtbank, waarbij het Huis van Afgevaardigden de rol van aanklager heeft en de Senaat de rol van rechtbankjury. Leden van het Congres kunnen een afzettingsprocedure initiëren, maar de aanzet kan in theorie ook van buiten het Congres komen. De commissie-Justitiële Zaken van het Huis van Afgevaardigden (en in sommige gevallen ook de House Committee on Rules) buigt zich over het verzoek. Veel van het voorwerk en het onderzoek vindt in deze commissie plaats. Als de commissie oordeelt dat Trump de wet heeft overtreden, dan stellen ze de zogeheten Articles of Impeachment op. In wezen is dit de formulering van de aanklacht: wat heeft de president precies fout gedaan? De commissie stuurt een aanbeveling naar het hele Huis van Afgevaardigden. De procedure bestaat vervolgens uit twee fases. De eerste is de impeachment zelf. Het Huis van Afgevaardigden moet oordelen of de overtreding van de wet zwaar genoeg is voor afzetting van de president. Een simpele meerderheid voldoet. Nadat het Huis van Afgevaardigden voor impeachment heeft gestemd, selecteert het een aantal ‘managers’. Die fungeren als aanklagers die de zaak presenteren aan de Senaat. Een impeachment is niet hetzelfde als een afzetting. Alleen de Senaat kan de president daadwerkelijk afzetten. In de Senaat begint dan ook de tweede fase: trial. De opperrechter van het Supreme Court leidt deze procedure en de senatoren worden beëdigd als juryleden. Zij beslissen uiteindelijk of impeachment ook daadwerkelijk tot afzetting leidt. Voor afzetting is een tweederde meerderheid vereist. Als de Senaat voor afzetting stemt, dan moet de president onmiddellijk aftreden. De uitspraak is niet aanvechtbaar via de rechter. Wel kan de afgezette president in aanmerking komen voor strafrechtelijke vervolging. In de Amerikaanse geschiedenis is nog nooit een presidentiële afzettingsprocedure met succes afgerond. Wel stemde een meerderheid van het Huis van Afgevaardigden twee keer voor een impeachment van een president (Andrew Johnson in 1868 en Bill Clinton in 1998). Het kwam in beide gevallen niet tot een daadwerkelijke afzetting, omdat er niet genoeg steun was in de Senaat. Tegen Nixon werden tijdens het Watergate-schandaal Articles of Impeachment opgesteld, maar het kwam niet tot een afzetting, omdat Nixon uit eigen beweging aftrad. Extra aanwijzingen voor dit topic: Helaas blijkt dit topic nogal eens te ontsporen. Het is een emotioneel onderwerp voor sommigen. Daarom de volgende afspraken: • Dit is geen linkdumptopic. Als je een tweet plaatst graag het volgende in ogenschouw nemen: Waarom deze tweet? Wat zegt het, wat vind je er zelf van? • Posts die tot doel hebben het topic te laten ontsporen, die respectloos zijn, of als linkdump aangemerkt kunnen worden, kunnen zonder overleg verwijderd worden door de moderatie. Want je post moet iets bijdragen aan de discussie en niet aan het op de kast jagen van users. • Het gaat hier over de Amerikaanse politiek. Niet over Amerika in zijn algemeen. Probeer on topic te blijven. • We gaan hier respectvol met elkaar om. Ook onderwerpen zoals kwetsbare migrantenkinderen worden met respect besproken. Ik zie er het nut niet van om bijv Michelle Obama als een kerel neer te zetten. Het enige doel om dat te doen is om users op de kast te jagen en het topic te laten ontsporen. Stop daar gewoon mee. Het voegt inhoudelijk niets toe. We gebruiken in dit topic normale bronnen. Hier te verifiëren: https://mediabiasfactcheck.com/ Voor visueel ingestelde mensen:
SnertMetChoco	zaterdag 3 oktober 2020 @ 11:30
	quote: Op zaterdag 3 oktober 2020 11:26 schreef westwoodblvd het volgende: [..] Ik denk dat ze stiekem een gat in de lucht zouden springen als ze het met Pence mogen doen. Doel je hier op het publiek? Voor de mensen in Congress denk ik dat ook wel, maar ik denk tegelijk dat Pence meer moeite heeft om het publiek aan te spreken die voor Trump gingen.
klappernootopreis	zaterdag 3 oktober 2020 @ 11:34
	Trump's campaign manager is ook besmet. Gaat lekker daar.
livelink	zaterdag 3 oktober 2020 @ 11:44
	Als ik toch religieus was en weigerde afstand te nemen en maskers te dragen omdat het nou eenmaal Gods wil is, dan zou dit toch een behoorlijk teken moeten zijn. God wil kennelijk niet dat Amy Barrett lid wordt van de SC en dat Trump nog een keer wordt herkozen. Nou ja, gelukkig denk ik niet zo, maar veel van de Republikeinse kiezers wel. Maar waarschijnlijk zullen zij er wel weer een draai aan geven. Dat het een ultieme test is van God of zo.
speknek	zaterdag 3 oktober 2020 @ 11:45
	Ik zei dat inderdaad ambigu, delen van de Republikeinse partij zullen ongetwijfeld blij zijn als ze eindelijk verlost van hun gijzelnemer zijn (andere delen zitten dan weer zo ver in de Cult dat ze subiet hun machtsbasis kwijtraken). Het Republikeinse publiek, wat vooral op de Trump persoonlijkheidscultus stemt, zal toch even moeten slikken of ze uit postume sympathie voor een Gristelijke engnek stemmen die het hoofd van de corona respons team was, waar Trump dan uiteindelijk aan dood gegaan zou zijn. Overigens zit Trump aan de remdesivir. Een redelijk goed werkend medicijn die normaal wel alleen aan de zware gevallen gegeven wordt, en hier nergens verkrijgbaar is. Ik denk wel dat hij het overleeft.
Ericr	zaterdag 3 oktober 2020 @ 11:52
	De herd mentality is in ieder geval wel aanwezig bij de republikeinen.
livelink	zaterdag 3 oktober 2020 @ 11:52
	quote: Op zaterdag 3 oktober 2020 11:45 schreef speknek het volgende: Ik zei dat inderdaad ambigu, delen van de Republikeinse partij zullen ongetwijfeld blij zijn als ze eindelijk verlost van hun gijzelnemer zijn (andere delen zitten dan weer zo ver in de Cult dat ze subiet hun machtsbasis kwijtraken). Het Republikeinse publiek, wat vooral op de Trump persoonlijkheidscultus stemt, zal toch even moeten slikken of ze uit postume sympathie voor een Gristelijke engnek stemmen die het hoofd van de corona respons team was, waar Trump dan uiteindelijk aan dood gegaan zou zijn. Overigens zit Trump aan de remdesivir. Een redelijk goed werkend medicijn die normaal wel alleen aan de zware gevallen gegeven wordt, en hier nergens verkrijgbaar is. Ik denk wel dat hij het overleeft. Ik denk ook dat hij het overleeft, maar het zal toch een enorme aanslag zijn op zijn weerstand. Heeft hij dan wel de energie om nog 4 jaar president te zijn (zelfs op de manier waarop hij het ambt invult)? Hij zal er vast niet ongeschonden uit komen op zijn leeftijd, vermoed ik. Niet dat het hem waarschijnlijk kan schelen. Zolang hij maar de macht houdt.
klappernootopreis	zaterdag 3 oktober 2020 @ 11:57
	quote: Op zaterdag 3 oktober 2020 11:45 schreef speknek het volgende: Het Republikeinse publiek, wat vooral op de Trump persoonlijkheidscultus stemt, zal toch even moeten slikken of ze uit postume sympathie voor een Gristelijke engnek stemmen die het hoofd van de corona respons team was, waar Trump dan uiteindelijk aan dood gegaan zou zijn. Daar maak je een sterk punt.
PippenScottie	zaterdag 3 oktober 2020 @ 12:03
	quote: Op zaterdag 3 oktober 2020 11:34 schreef klappernootopreis het volgende: Trump's campaign manager is ook besmet. Gaat lekker daar. Campagnemanager van Trump zijn is een beetje de gevaarlijkste job ter wereld. Het duurt niet lang, gevangenisstraf is praktisch gegarandeerd en Corona is ook bijna een zekerheidje.
Ulx	zaterdag 3 oktober 2020 @ 12:12
	twitter O jee
Ulx	zaterdag 3 oktober 2020 @ 12:16
	Boomers hebben Kennedy vermoord zien worden. The Greatest Generation had Roosevelt die stierf in office. Wat krijgen wij? Fucking Trump die croaked aan een hoax. Het leven is oneerlijk.
Eyjafjallajoekull	zaterdag 3 oktober 2020 @ 13:17
	Y'all got any more of them updates? Verslavend wil dit soort nieuws momenten Zit elk uur te checken of er niet wat meer bekend is over zijn gezondheid.
Monolith	zaterdag 3 oktober 2020 @ 13:27
	quote: Op zaterdag 3 oktober 2020 13:17 schreef Eyjafjallajoekull het volgende: Y'all got any more of them updates? Verslavend wil dit soort nieuws momenten Zit elk uur te checken of er niet wat meer bekend is over zijn gezondheid. Het is nog nacht / vroege ochtend in de VS. Bovendien gaan er wel een paar dagen overheen voordat duidelijk is hoe het ziektebeeld van Trump zich ontwikkeld waarschijnlijk.
Lord-Ronddraai	zaterdag 3 oktober 2020 @ 13:29
	Ik zag een goede post van Michael Moore langskomen quote: So Now Trump Has Earned Your Trust? A Note of Covid Caution from Michael Moore.... There is one absolute truth about Trump: He is a consistent, absolute, unrelenting, fearless, and professional liar. A serial liar. A factually proven liar. How many lies now has the Washington Post proven in these four years? 25,000? A lie at least twice during every waking hour? Think of all the bad people you’ve known in your life. Even the worst ones you couldn’t say that about. So why on earth would we believe him today? Has he earned your trust now? No. Yet, we’re decent enough to not want him to be sick, to wish him well, and maybe just this once give him the benefit of the doubt because why would he lie about this? That’s not the question. The question we — and yes, I mean you, too, the media — the only question we really need to be asking is this: Why would Trump all of a sudden just start telling the truth? All of you, my friends, have been saying for four years, “Trump’s a liar! Trump is a liar!” Why would you believe him now? He very well may have COVID-19. In fact, let’s assume he does. Of course he has it! Does that make him not Trump? I’m certain Mussolini came down with the flu one time. Pinochet and Franco would catch a cold every now and then. Margaret Thatcher must have had a migraine or two. None of them suddenly became nice or did good things - or started telling the truth - because they got sick. Jesse Helms with a runny nose was still Jesse Helms. But Trump has a history of lying about his health. His longtime New York doctor, Dr. Bornstein, admitted a few years ago that Trump dictated his perfect “doctor’s letter” during the 2016 campaign. Then there was the White House doctor who said Trump could live “200 years!” What about his lying about that emergency trip to Walter Reed “to complete his physical?” Trump also has a history of lying about his opponents’ health (like when Hillary fell ill at the 9/11 remembrance ceremony, or what he’s now been saying about Biden’s health). So we must be skeptical. We must always remain skeptical when it comes to Trump. He may have it. But it’s also possible he’s lying. That’s just a fact. But why would he lie about this? What would he have to gain? I mean, it looks bad that he’s called it a hoax for seven months, and he totally mismanaged the government response — and now he has it? Doesn’t it look terrible that he’s spent months downplaying wearing masks, dismissing social distancing, holding large rallies filled with elderly, at-risk supporters and even killing his own supporters like Herman Cain? And doesn’t this go against his brand of always projecting (and exaggerating) his own strength, his health, his genetics, his virility? Yes. This is all true. He would not want to admit he‘s come down with a hoax. But — he’s losing the election. And he knows it. It’s not 2016. He was hated in 2016, but he’s hated even more now. Millions of Americans are ON FIRE and on the verge of serving him up a major league ass-whooping and a record landslide defeat. So he needs - badly - to totally change the conversation about this campaign. And he just has. Democrats, liberals, the media and others have always been wrong to simply treat him as a buffoon and a dummy and a jackass. Yes, he is all those things. But he’s also canny. He’s clever. He outfoxed Comey. He outfoxed Mueller. He outfoxed 20 Republicans in the GOP primary and then did the same to the Democrats, winning the White House despite receiving fewer votes than his opponent. He’s an evil genius and I raise the possibility of him lying about having COVID-19 to prepare us and counteract his game. He knows being sick tends to gain one sympathy. He’s not above weaponizing this. He’s been lying about how soon a vaccine will be ready. What better way to hammer home that lie then by directing a saga in the final weeks before the election that culminates in the release of this “vaccine.” The NY Times tax story was horrible for him. As was The Atlantic story about him calling American troops losers and suckers. There are a dozen more of these stories coming in October. Just last night, The New Yorker detailed how his campaign finance director (and Don Jr’s girlfriend) was fired from Fox News for....well...behaving like a typical Fox News host by sexually harassing her assistant and forcing Fox to pay a $4 million settlement to that assistant due to her behavior. And also, last night, there was CNN playing an audio recording of Melania talking shit about children separated from their parents at the border — AND talking shit about Christmas. Christmas! These stories are about to be a daily occurrence. However, they may get less airtime and be less damaging since Trump and FLOTUS are now “sick” and supposed to be in our thoughts and prayers. But most dangerously, HE MAY USE THIS TO PUSH FOR DELAYING/POSTPONING THE ELECTION. The constitution does not allow for this, but he doesn’t give a f*ck about the constitution. He and his thug Attorney General Barr have no shame and will stop at nothing to stay in power. He may even use this as an excuse for losing. Then there’s this: He may use his Covid as a pretext to drop out of the race and move Pence to the top of the ticket. Pence would temporarily become President, and then Pence could pre-emptively pardon Trump for all of his crimes. Again, though, he may have COVID. He probably does. But never, ever, ever take him at his word and never, ever, ever underestimate his survival skills or the depths of his deception or his evil.
Eyjafjallajoekull	zaterdag 3 oktober 2020 @ 13:30
	quote: Op zaterdag 3 oktober 2020 13:27 schreef Monolith het volgende: [..] Het is nog nacht / vroege ochtend in de VS. Bovendien gaan er wel een paar dagen overheen voordat duidelijk is hoe het ziektebeeld van Trump zich ontwikkeld waarschijnlijk. Uiteraard. Kan zo een week of langer duren. Maar er is zijn natuurlijk meer ontwikkelingen zoals de mensen om hem heen.
Toby56	zaterdag 3 oktober 2020 @ 13:43
	Deze column was geschreven voor de laatste ontwikkelingen; niettemin (volgens mij) toch lezenswaardig. https://www.theguardian.c(...)diagnosis-maga-virus [...] The very last thing Trump would wish to imply is that his life is worth any more than the lives of all those people who were dying when he was joking about masks, joking about Joe Biden and masks, joking about Biden being practically dead ... to say nothing of all those times past when he joked about Hillary Clinton’s pneumonia, or had his proxies joke speculatively that she had suffered a stroke, or was afflicted by dysphasia, or had secretly suffered a serious brain trauma … I’m sorry, I’m running very low on space here. The point is, this is what he’d WANT – because he loves the lulz. Please honour him thusly. Anyway, as Trump pointed out last week, the virus “affects virtually nobody”, and has currently only affected 200,000 American nobodies to death. [...] Een interessante vraag is natuurlijk: wil je net zo diep zakken als Trump zelf? Of, als je nu eenmaal een empathische persoonlijkheid hebt, wens je hem toch beterschap?
SnertMetChoco	zaterdag 3 oktober 2020 @ 13:52
	quote: Op zaterdag 3 oktober 2020 13:17 schreef Eyjafjallajoekull het volgende: Y'all got any more of them updates? Verslavend wil dit soort nieuws momenten Zit elk uur te checken of er niet wat meer bekend is over zijn gezondheid. Dit is zo'n beetje de afgelopen 4 jaar, maar dan niet alleen over zijn gezondheid.
AnneX	zaterdag 3 oktober 2020 @ 14:05
	Eindelijk gelegenheid om een interview met de Mooch te zien. Een link van tig topics geleden. Mèn, iedere zin uit zijn mond is een soundbite. Nog geen 160. 000 views. The Choice 2020: Anthony Scaramucci (interview) \| FRONTLINE
Ulx	zaterdag 3 oktober 2020 @ 14:20
	twitter Oh boy, straks blijkt nog dat zijn leven werd gered door goddeloos stamcelonderzoek, gedaan op geaborteerde foetussen die uit vrouwen zijn gehaald die dachten goede winst te kunnen maken door het ongeboren leven te verkopen aan big pharma.
Ulx	zaterdag 3 oktober 2020 @ 14:22
	twitter Biden is voor jan lul gestopt met negatieve spotjes.